The ACTB Knockout 769-P Polyclonal Cells constitute a heterogeneous CRISPR/Cas9-edited population derived from the 769-P human renal adenocarcinoma epithelial cell line, in which the ACTB gene has been disrupted. As a polyclonal knockout product, this pool comprises a mixture of cells carrying diverse gene-editing events, providing a robust loss-of-function model without single-cell cloning. The absence of clonal selection ensures that the population retains genetic diversity, minimizing clonal artifacts and representing a more biologically relevant system for studying ACTB-dependent phenotypes. This product is designed to enable investigation of beta-actin function in a clear cell renal cell carcinoma (ccRCC) background.
The parental 769-P cell line is a well-established model of human ccRCC, originating from a primary renal adenocarcinoma. These epithelial cells exhibit characteristics typical of aggressive renal cancers, including alterations in the VHL-HIF pathway, and are extensively used to explore tumor biology, drug resistance, and metastatic mechanisms. Their adherent growth and in vitro behavior make them suitable for a wide range of imaging and biochemical assays. Thus, the 769-P line offers a physiologically relevant platform to study cytoskeletal contributions to renal cancer.
Beta-actin, encoded by ACTB, is a ubiquitous and essential cytoskeletal protein that polymerizes into microfilaments, providing structural integrity and driving cell motility. Its dynamic remodeling is tightly controlled by upstream Rho GTPases: RhoA activates ROCK and LIMK, which phosphorylate cofilin to inhibit actin depolymerization, whereas Rac1 and Cdc42 promote actin branching via the ARP2/3 complex and formins, leading to lamellipodia and filopodia formation. Beta-actin interacts with numerous partners, including myosins, tropomyosins, filamins, and spectrins, to regulate contractility, crosslinking, and membrane anchorage. This signaling network integrates cues from integrins, FAK, and Src to coordinate cell adhesion and migration, with direct implications for tumor cell invasion.
Knockout of ACTB in the 769-P ccRCC model disrupts the actin cytoskeleton, impairing cell migration, polarization, and focal adhesion turnover. As beta-actin is critical for the invasive properties of cancer cells, this model enables the study of metastasis-associated processes in a renal carcinoma context. The loss of ACTB may also affect Hippo signaling and mechanical transduction, providing insights into how cytoskeletal integrity influences tumor progression. Given the high metastatic propensity of ccRCC, this knockout system offers a valuable tool to dissect actin-dependent mechanisms driving cancer dissemination.
Researchers can employ the ACTB Knockout 769-P Polyclonal Cells in various functional assays, including Western blotting to confirm protein loss, phalloidin staining to visualize F-actin reorganization, wound healing and Transwell migration/invasion assays to assess motility, and live-cell imaging to monitor actin dynamics in real time. RNA-seq analyses can reveal transcriptional adaptations to cytoskeletal disruption. These applications support studies ranging from basic cytoskeletal biology to drug screening for anti-metastatic compounds. For further information, please contact Ascent Research.
